Ozempic (semaglutide injection)
Still the largest single product, but sales are falling year to date.
The numbers
What it is
Weekly semaglutide injection for type 2 diabetes. It is the largest product in the company and the base for much of the GLP-1 franchise.
Why it matters to the stock. Ozempic is the biggest revenue line, so pricing pressure here affects the whole company even as obesity grows.
News
Novo Nordisk Q2 2026 profit beats forecasts and raises full-year outlook
Novo reported Q2 2026 adjusted sales of DKK 78,488 million, up 7% at constant exchange rates, and adjusted operating profit of DKK 33,389 million, up 11%.
Earnings